Journal of Clinical Endocrinology & Metabolism, Vol 70, 1518-1524, Copyright © 1990 by Endocrine Society

ARTICLES

Current trends in the management of Graves' disease

B Solomon, D Glinoer, R Lagasse and L Wartofsky
Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, D.C. 20307.

Members of the American Thyroid Association were invited to participate in a survey of the management of Graves' disease. One primary case and several variations were provided, which differed in respect to age, sex, goiter size, severity, etc. The questionnaire was based on the format used in a similar survey of members of the European Thyroid Association. The aim of the survey was to determine 1) how expert thyroidologist employ diagnostic procedures for this disorder, and 2) the choice of therapy of the three treatment options and its manner of implementation. Questionnaires were sent only to clinically active members. The overall response rate was 62%. Data analysis was possible on 52% of members surveyed and was performed using SPSS and a specific Fortran program. In the laboratory evaluation of the primary case a radioiodine uptake, scan, serum total T4, and basal TSH were requested by 92%, 47%, 83%, and 66%, respectively, with 84% of respondents using an ultrasensitive TSH assay. For management of the primary case, radioiodine treatment was the first choice of 69% of the respondents. Antithyroid drugs were used briefly (3-7 days) before 131I by 28%, whereas 41% said they would employ thioureas after 131I. Of those using 131I, 66% tailored the dose to achieve euthyroidism as the goal of therapy, while 34% aimed for hypothyroidism requiring T4 replacement. Only 30% of respondents chose thioureas as a first line of treatment (72% propylthiouracil; 28% tapazole). The duration of drug therapy was a predetermined fixed interval for 80% of the respondents, with 90% treating for 1-2 yr. Other specific trends in diagnostic approach and therapeutic preferences were identified for the eight variations on the primary case problem.

This article has been cited by other articles:

				A. Toft and T. C Sandeep Radioiodine treatment of hyperthyroidism BMJ, March 10, 2007; 334(7592): 483 - 484. [Full Text] [PDF]

				M. A Walter, M. Briel, M. Christ-Crain, S. J Bonnema, J. Connell, D. S Cooper, H. C Bucher, J. Muller-Brand, and B. Muller Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials BMJ, March 10, 2007; 334(7592): 514 - 514. [Abstract] [Full Text] [PDF]

				A. Iagaru and I. R. McDougall Treatment of Thyrotoxicosis J. Nucl. Med., March 1, 2007; 48(3): 379 - 389. [Abstract] [Full Text] [PDF]

				T. Watt, M. Groenvold, A. K. Rasmussen, S. J. Bonnema, L. Hegedus, J. B. Bjorner, and U. Feldt-Rasmussen Quality of life in patients with benign thyroid disorders. A review. Eur. J. Endocrinol., April 1, 2006; 154(4): 501 - 510. [Abstract] [Full Text] [PDF]

				P. Abraham, A. Avenell, C. M Park, W. A Watson, and J. S Bevan A systematic review of drug therapy for Graves' hyperthyroidism Eur. J. Endocrinol., October 1, 2005; 153(4): 489 - 498. [Abstract] [Full Text] [PDF]

				D. S. Cooper Antithyroid Drugs N. Engl. J. Med., March 3, 2005; 352(9): 905 - 917. [Full Text] [PDF]

				S. J. Bonnema and L. Hegedus Authors' Response: Treatment with Thionamides before Radioiodine Therapy for Hyperthyroidism: Yes or No? J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1256 - 1257. [Full Text] [PDF]

				S. J. Bonnema, F. N. Bennedbaek, A. Veje, J. Marving, and L. Hegedus Propylthiouracil before 131I Therapy of Hyperthyroid Diseases: Effect on Cure Rate Evaluated by a Randomized Clinical Trial J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4439 - 4444. [Abstract] [Full Text] [PDF]

				D. S. Cooper Antithyroid Drugs in the Management of Patients with Graves' Disease: An Evidence-Based Approach to Therapeutic Controversies J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3474 - 3481. [Full Text] [PDF]

				D. D Streetman and U. Khanderia Diagnosis and Treatment of Graves Disease Ann. Pharmacother., July 1, 2003; 37(7): 1100 - 1109. [Abstract] [Full Text] [PDF]

				C. M. Intenzo, A. E. dePapp, S. Jabbour, J. L. Miller, S. M. Kim, and D. M. Capuzzi Scintigraphic Manifestations of Thyrotoxicosis RadioGraphics, July 1, 2003; 23(4): 857 - 869. [Abstract] [Full Text] [PDF]

				J. Ginsberg Diagnosis and management of Graves' disease Can. Med. Assoc. J., March 4, 2003; 168(5): 575 - 585. [Abstract] [Full Text] [PDF]

				W. D. Leslie, L. Ward, E. A. Salamon, S. Ludwig, R. C. Rowe, and E. A. Cowden A Randomized Comparison of Radioiodine Doses in Graves' Hyperthyroidism J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 978 - 983. [Abstract] [Full Text] [PDF]

				E. K. Alexander and P. R. Larsen American Board of Internal Medicine. 2002 Certification Examination in Endocrinology, Diabetes, and Metabolism J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1073 - 1077. [Abstract] [Full Text] [PDF]

				H. B. Burch, B. L. Solomon, D. S. Cooper, P. Ferguson, N. Walpert, and R. Howard The Effect of Antithyroid Drug Pretreatment on Acute Changes in Thyroid Hormone Levels after 131I Ablation for Graves' Disease J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3016 - 3021. [Abstract] [Full Text] [PDF]

				A. P. Weetman Graves' Disease N. Engl. J. Med., October 26, 2000; 343(17): 1236 - 1248. [Full Text] [PDF]

				F Escobar-Jiménez, M L Férnandez-Soto, V Luna-López, M Quesada-Charneco, and D Glinoer Trends in diagnostic and therapeutic criteria in Graves' disease in the last 10 years Postgrad. Med. J., June 1, 2000; 76(896): 340 - 344. [Abstract] [Full Text]

				L. Bartalena, A. Pinchera, and C. Marcocci Management of Graves' Ophthalmopathy: Reality and Perspectives Endocr. Rev., April 1, 2000; 21(2): 168 - 199. [Abstract] [Full Text]

				F. Bogazzi, L. Bartalena, S. Brogioni, G. Scarcello, A. Burelli, A. Campomori, L. Manetti, G. Rossi, A. Pinchera, and E. Martino Comparison of Radioiodine with Radioiodine plus Lithium in the Treatment of Graves' Hyperthyroidism J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 499 - 503. [Abstract] [Full Text]

				D. S. Cooper Radioiodine for Hyperthyroidism: Where Do We Stand After 50 Years? JAMA, July 22, 1998; 280(4): 375 - 376. [Full Text] [PDF]

				A. Lucas, I. Salinas, F. Rius, E. Pizarro, M.L. Granada, M. Foz, and A. SanmartI Medical Therapy of Graves' Disease: Does Thyroxine Prevent Recurrence of Hyperthyroidism? J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2410 - 2413. [Abstract] [Full Text] [PDF]